as 11-15-2024 4:00pm EST
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Founded: | 2012 | Country: | Canada |
Employees: | N/A | City: | VANCOUVER |
Market Cap: | 719.0M | IPO Year: | 2020 |
Target Price: | $8.50 | AVG Volume (30 days): | 2.6M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.61 | EPS Growth: | N/A |
52 Week Low/High: | $2.33 - $6.06 | Next Earning Date: | 11-04-2024 |
Revenue: | $32,962,000 | Revenue Growth: | -34.59% |
Revenue Growth (this year): | -13.15% | Revenue Growth (next year): | 38.78% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Thermopylae Holdings Ltd. | ABCL | 10% Owner | Aug 29 '24 | Buy | $2.61 | 283,516 | $739,976.76 | 56,086,009 |
ABCL Breaking Stock News: Dive into ABCL Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Simply Wall St.
10 days ago
Simply Wall St.
11 days ago
Thomson Reuters StreetEvents
12 days ago
GuruFocus.com
12 days ago
Motley Fool
12 days ago
Zacks
13 days ago
Business Wire
13 days ago
The information presented on this page, "ABCL AbCellera Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.